Strength of PD-1 signaling differentially affects T-cell effector functions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 27, 2013, Pages

  Wei, Fang ^a,b   Zhong, Shi ^c   Ma, Zhengyu ^d   Kong, Hong ^a,b   Medvec, Andrew ^a,b   Ahmed, Rafi ^e   Freeman, Gordon J ^f,g   Krogsgaard, Michelle ^c   Riley, James L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HIV 1 specific T cell response; Peptide counting; TCR signaling

Indexed keywords

CALCIUM ION; GAMMA INTERFERON; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CALCIUM TRANSPORT; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EFFECTOR CELL; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

HIV-1 SPECIFIC T CELL RESPONSE; PEPTIDE COUNTING; TCR SIGNALING;

CALCIUM SIGNALING; CELLS, CULTURED; CHEMOKINE CCL4; CYTOTOXICITY, IMMUNOLOGIC; HIV-1; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MODELS, IMMUNOLOGICAL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879703551     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1305394110     Document Type: Article

References (60)

1. Williams MA, Bevan MJ (2007) Effector and memory CTL differentiation. Annu Rev Immunol 25:171-192. (Pubitemid 46697906)
2. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492-499.
3. Wherry EJ, Blattman JN,Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77(8):4911-4927. (Pubitemid 36402840)
4. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-687. (Pubitemid 43237609)
5. Shin H, et al. (2009) A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31(2):309-320.
6. Riley JL, June CH (2007) The road to recovery: Translating PD-1 biology into clinical benefit. Trends Immunol 28(2):48-50. (Pubitemid 46176731)
7. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19(7):813-824. (Pubitemid 47241890)
8. Zhang X, et al. (2004) Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20(3):337-347. (Pubitemid 38388235)
9. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Ann Rev Immunol 23:515-548. (Pubitemid 40563179)
10. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704. (Pubitemid 351600389)
11. Boni C, et al. (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81(8):4215-4225. (Pubitemid 46586915)
12. Radziewicz H, et al. (2007) Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 81(6):2545-2553. (Pubitemid 46447020)
13. Brahmer JR, et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167-3175.
14. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opinion Immunol 2:207-212.
15. Duraiswamy J, et al. (2011) Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 186(7):4200-4212.
16. Blackburn SD, et al. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10(1):29-37.
17. Zhou Q, et al. (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117(17):4501-4510.
18. McMahan RH, et al. (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120(12):4546-4557.
19. Day CL, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350-354. (Pubitemid 44435155)
20. Petrovas C, et al. (2006) PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203(10):2281-2292. (Pubitemid 44498363)
21. Trautmann L, et al. (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12(10):1198-1202. (Pubitemid 44527357)
22. Riley JL (2009) PD-1 signaling in primary T cells. Immunol Rev 229(1):114-125.
23. Bennett F, et al. (2003) Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 170(2):711-718. (Pubitemid 36070520)
24. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945-954. (Pubitemid 38924267)
25. Parry RV, et al. (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25(21):9543-9553. (Pubitemid 41507854)
26. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98(24):13866-13871. (Pubitemid 33115990)
27. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL (2006) B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 176(11):6603-6614. (Pubitemid 43787843)
28. Patsoukis N, et al. (2012) Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal 5 (230):ra46.
29. Patsoukis N, Sari D, Boussiotis VA (2012) PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 11(23):4305-4309.
30. Varela-Rohena A, et al. (2008) Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14(12):1390-1395.
31. Gallo EM, Canté-Barrett K, Crabtree GR (2006) Lymphocyte calcium signaling from membrane to nucleus. Nat Immunol 7(1):25-32. (Pubitemid 41823865)
32. Wang S-F, et al. (2011) Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS ONE 6(3):e17621.
33. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM (2002) Direct observation of ligand recognition by T cells. Nature 419(6909):845-849. (Pubitemid 35238571)
34. Purbhoo MA, Irvine DJ, Huppa JB, Davis MM (2004) T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol 5(5):524-530. (Pubitemid 38660465)
35. Li QJ, et al. (2004) CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. Nat Immunol 5(8):791-799.
36. Messal N, Serriari NE, Pastor S, Nunès JA, Olive D (2011) PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol 48(15-16):2214-2219.
37. Lichterfeld M, et al. (2008) Telomerase activity of HIV-1-specific CD8+ T cells: Constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 112(9):3679-3687.
38. Blackburn SD, Shin H, Freeman GJ, Wherry EJ (2008) Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA 105(39):15016-15021.
39. Blackburn SD, et al. (2010) Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: Implications for CD8 T-cell exhaustion. J Virol 84(4):2078-2089.
40. Urbani S, et al. (2008) Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. J Hepatol 48(4):548-558.
41. D'Souza M, et al. (2007) Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 179(3):1979-1987.
42. Zhang J-Y, et al. (2007) PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109(11):4671-4678. (Pubitemid 46827757)
43. Porichis F, et al. (2011) Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 118(4):965-974.
44. Fourcade J, et al. (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182(9):5240- 5249.
45. Fourcade J, et al. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10):2175-2186.
46. Wong RM, et al. (2007) Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 19(10):1223-1234. (Pubitemid 47500645)
47. Zhang Z, et al. (2009) Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol 50(6):1163-1173.
48. Nakamoto N, et al. (2008) Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134(7):1927-1937.
49. Bhadra R, Gigley JP, Weiss LM, Khan IA (2011) Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc Natl Acad Sci USA 108(22):9196-9201.
50. Butler NS, et al. (2012) Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 13(2):188-195.
51. Velu V, et al. (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235):206-210.
52. Dyavar Shetty R, et al. (2012) PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 122(5):1712-1716.
53. Keir ME, Latchman YE, Freeman GJ, Sharpe AH (2005) Programmed death-1 (PD-1): PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol 175(11):7372-7379. (Pubitemid 41713434)
54. Sheppard KA, et al. (2004) PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 574(1-3):37-41.
55. Suhoski MM, et al. (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15(5):981-988. (Pubitemid 46621657)
56. Zhao Y, et al. (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70(22):9053-9061.
57. Salter RD, Howell DN, Cresswell P (1985) Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21(3):235-246. (Pubitemid 15117182)
58. Golovina TN, et al. (2011) Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE 6(1):e15868.
59. Hermans IF, et al. (2004) The VITAL assay: A versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 285(1):25-40. (Pubitemid 38186583)
60. Plesa G, et al. (2012) TCR affinity and specificity requirements for human regulatory T-cell function. Blood 119(15):3420-3430.